[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100648580":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":24,"locations":11,"responsibleParty":34,"collaborators":36,"id":40,"slug":41,"hasResults":42,"nctId":43,"briefTitle":44,"officialTitle":44,"acronym":45,"eligibilityCriteria":46,"healthyVolunteers":42,"sex":47,"minAge":48,"maxAge":11,"enrollmentInfo":49,"targetDuration":11,"studyType":52,"phases":53,"briefSummary":55,"conditions":56,"keywords":59,"overallStatus":63,"whyStopped":11,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":11},{"fullName":5,"class":6},"Fondazione Don Carlo Gnocchi ETS","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Integrated Precision Medicine Intervention","EXPERIMENTAL",null,[13],"Other: Integrated Precision Medicine Platform",[15],{"type":6,"name":16,"description":17,"armGroupLabels":18,"otherNames":11},"Integrated Precision Medicine Platform","Participants will undergo an integrated precision medicine intervention for inflammatory lung diseases, including multi-omics biomarker assessment, clinical and environmental monitoring, and telemedicine-supported follow-up. The intervention includes the collection of biological samples for biomarker profiling, assessment of indoor and outdoor environmental exposures, and continuous monitoring of clinical and environmental parameters. Where applicable, participants will receive a precision inhalation medical device designed to optimize drug delivery. Data from biomarker analyses, monitoring devices, and the telemedicine platform will be integrated to support personalized disease management and the early identification of disease exacerbations.",[9],[20],{"name":21,"affiliation":22,"role":23},"Luca Bianchi","Fondazione Don Gnocchi ETS","PRINCIPAL_INVESTIGATOR",[25,30],{"name":26,"role":27,"phone":28,"phoneExt":11,"email":29},"Mario Clerici, MD","CONTACT","+390240308244","mario.clerici@unimi.it",{"name":31,"role":27,"phone":32,"phoneExt":11,"email":33},"Simone Agostini, PhD","+390240308375","sagostini@dongnocchi.it",{"type":35,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR",[37],{"name":38,"class":39},"Programma Regionale FESR - Regione Lombardia","UNKNOWN","100648580","new-diagnostic-approaches-in-the-management-of-inflammatory-lung-diseases-100648580",false,"NCT07723638","New Diagnostic Approaches in the Management of Inflammatory Lung Diseases","ALPI","Inclusion Criteria:\n\n* Adults aged 18 years or older.\n* Diagnosis of chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF), or combined pulmonary fibrosis and emphysema (CPFE), established according to current international diagnostic guidelines.\n* Ability and willingness to provide written informed consent.\n* Willingness to provide blood and saliva samples for biomarker analyses.\n* Willingness and ability to undergo clinical assessments and scheduled follow-up visits.\n* Willingness and ability to use study monitoring devices, including environmental monitoring devices and, where applicable, telemedicine tools.\n\nExclusion Criteria:\n\n* Age younger than 18 years.\n* Inability or unwillingness to provide written informed consent.\n* Inability to comply with study procedures or scheduled follow-up.\n* Presence of any medical, psychiatric, or cognitive condition that, in the opinion of the investigator, would interfere with study participation or interpretation of the study results.\n* Participation in another interventional clinical trial that, in the opinion of the investigator, could interfere with the objectives of this study.","ALL","18 Years",{"count":50,"type":51},200,"ESTIMATED","INTERVENTIONAL",[54],"NA","Inflammatory lung diseases, including chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF), are major causes of morbidity and mortality worldwide. Their development and progression are influenced by environmental exposures, such as cigarette smoking and air pollution, as well as genetic susceptibility. Despite advances in disease management, early diagnosis, accurate differential diagnosis, personalized treatment, and continuous monitoring remain significant clinical challenges.\n\nThis project aims to improve the management of inflammatory lung diseases through the development and validation of innovative diagnostic, monitoring, and therapeutic approaches. The study will identify and validate multi-omics biomarkers for the differential diagnosis and prognosis of COPD, IPF, and related respiratory diseases, using machine learning techniques to develop diagnostic and prognostic biochips. Environmental determinants, including indoor and outdoor exposome factors, will be assessed to better understand their contribution to pulmonary inflammation and disease progression. The project will also develop nanotechnology-based therapeutic formulations combined with precision inhalation devices and integrate a telemedicine platform for real-time monitoring of clinical and environmental data, enabling the early detection of exacerbations and supporting personalized disease management.\n\nThe expected outcomes include improved diagnostic accuracy, enhanced risk stratification, personalized therapeutic strategies, reduced disease exacerbations, and improved quality of life for patients with inflammatory lung diseases.",[57,58],"Chronic Obstructive Pulmonary Disease (COPD)","Idiopathic Pulmonary Fibrosis",[60,61,62],"Biomarkers","COPD","IPF","NOT_YET_RECRUITING","2026-07-21",{"date":66,"type":67},"2026-07-23","ACTUAL",{"date":69,"type":51},"2026-09-01",{"date":71,"type":51},"2027-11-13",{"name":5,"class":6}]